ACP3 and prostate carcinoma: Similarly, peripheral-blood mononuclear cells (PBMCs) and antigen-presenting cells (APCs) activated with a fusion protein (PA2024) possessing prostate antigen prostatic acid phosphatase (PAP) fused to macrophage-colony-stimulating factor (GM-CSF) are also used in the prostate cancer vaccine [124,125].